A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients

Basit Öğe Kaydı
dc.authoridAksu, Kenan/0000-0001-8889-2688
dc.authoridYıldız, Fatih/0000-0003-3628-8870
dc.authoridkucuksahin, orhan/0000-0003-4530-2304
dc.authoridAkkoc, Nurullah/0000-0002-3718-171X
dc.authoridmercan, ridvan/0000-0003-1537-2192;
dc.authorwosidpehlivan, yavuz/AAG-8227-2021
dc.authorwosidAksu, Kenan/HLH-8218-2023
dc.authorwosidYıldız, Fatih/P-2555-2018
dc.authorwosidCefle, Ayse/AAT-3653-2020
dc.authorwosidkucuksahin, orhan/GZA-3287-2022
dc.authorwosidAkkoc, Nurullah/D-9870-2011
dc.authorwosidmercan, ridvan/W-3342-2017
dc.contributor.authorPamuk, Omer Nuri
dc.contributor.authorKalyoncu, Umut
dc.contributor.authorAksu, Kenan
dc.contributor.authorOmma, Ahmet
dc.contributor.authorPehlivan, Yavuz
dc.contributor.authorCagatay, Yonca
dc.contributor.authorKucuksahin, Orhan
dc.date.accessioned2024-06-12T11:13:58Z
dc.date.available2024-06-12T11:13:58Z
dc.date.issued2016
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIn this multicenter, retrospective study, we evaluated the efficacy and safety of biologic therapies, including anti-TNFs, in secondary (AA) amyloidosis patients with ankylosing spondylitis (AS) and rheumatoid arthritis (RA). In addition, the frequency of secondary amyloidosis in RA and AS patients in a single center was estimated. Fifty-one AS (39M, 12F, mean age: 46.7) and 30 RA patients (11M, 19F, mean age: 51.7) with AA amyloidosis from 16 different centers in Turkey were included. Clinical and demographical features of patients were obtained from medical charts. A composite response index (CRI) to biologic therapy-based on creatinine level, proteinuria and disease activity-was used to evaluate the efficacy of treatment. The mean annual incidence of AA amyloidosis in RA and AS patients was 0.23 and 0.42/1000 patients/year, respectively. The point prevalence in RA and AS groups was 4.59 and 7.58/1000, respectively. In RA group with AA amyloidosis, effective response was obtained in 52.2 % of patients according to CRI. RA patients with RF positivity and more initial disease activity tended to have higher response rates to therapy (p values, 0.069 and 0.056). After biologic therapy (median 17 months), two RA patients died and two developed tuberculosis. In AS group, 45.7 % of patients fulfilled the criteria of good response according to CRI. AS patients with higher CRP levels at the time of AA diagnosis and at the beginning of anti-TNF therapy had higher response rates (p values, 0.011 and 0.017). During follow-up after anti-TNF therapy (median 38 months), one patient died and tuberculosis developed in two patients. Biologic therapy seems to be effective in at least half of RA and AS patients with AA amyloidosis. Tuberculosis was the most important safety concern.en_US
dc.identifier.doi10.1007/s00296-016-3500-9
dc.identifier.endpage953en_US
dc.identifier.issn0172-8172
dc.identifier.issn1437-160X
dc.identifier.issue7en_US
dc.identifier.pmid27221456en_US
dc.identifier.scopus2-s2.0-84971619944en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage945en_US
dc.identifier.urihttps://doi.org/10.1007/s00296-016-3500-9
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23756
dc.identifier.volume36en_US
dc.identifier.wosWOS:000378883700007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofRheumatology Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSecondary Amyloidosisen_US
dc.subjectRheumatoid Arthritisen_US
dc.subjectAnkylosing Spondylitisen_US
dc.subjectBiologic Therapyen_US
dc.subjectAnti-TNFen_US
dc.subjectAa Amyloidosisen_US
dc.subjectEtanercepten_US
dc.subjectEfficacyen_US
dc.subjectCriteriaen_US
dc.subjectTocilizumaben_US
dc.subjectPrevalenceen_US
dc.subjectInfliximaben_US
dc.subjectResolutionen_US
dc.subjectTherapyen_US
dc.subjectSafetyen_US
dc.titleA multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu